Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

PREGABALIN

All products: general benefit

Other products in the same Health Canada class (N02BF) — coverage varies; not interchangeable

  • Gabapentin (Neurontin): general benefit, Not a benefit

Lyrica · DIN 02268426 · 50mg · capsule

General benefitMarketed · checked 2026-09-20
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Savings card: RxHelp ONE lists Lyrica (read 2026-09-10) — brand-name savings card, free; cannot be combined with another card on the same claim. (rxhelp.ca ↗)
1 brand, same coverage
Lyrica · DIN 02268426 Manufacturer: Upjohn Canada ULC; listing date 2013-04-30 Health Canada: Marketed since 2023-05-11 · brand LYRICA · ATC N02BF02 PREGABALIN · form Capsule · route Oral · ingredients PREGABALIN 50 MG · company Bgp pharma ulc · schedule Prescription
Check this DIN again · Health Canada product record

Ministry pays: $0.2324 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=75380 · Verify on the e-Formulary ↗ (DIN 02268426)

Source record
DIN 02268426: Lyrica Raw flags: sec3=Y Item: 281200095; group id 442; item number 1104; lccId None; manufacturer id UJC Source form: Cap; strength: 50mg Recorded listing: General benefit Source prices (unrounded): $1.6034; ministry $0.2324 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02268426 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=75380
Interchangeable products
AG-Pregabalin · DIN 02480735 · $0.2324 Ach-Pregabalin · DIN 02449846 · $0.2324 Apo-Pregabalin · DIN 02394243 · $0.2324 Auro-Pregabalin · DIN 02433877 · $0.2324 Bio-Pregabalin · DIN 02541130 · $0.2324 Co Pregabalin · DIN 02402920 · $0.2324 Jamp-Pregabalin · DIN 02435985 · $0.2324 M-Pregabalin · DIN 02467305 · $0.2324 Mar-Pregabalin · DIN 02417537 · $0.2324 Mint-Pregabalin · DIN 02423812 · $0.2324 NRA-Pregabalin · DIN 02479125 · $0.2324 Nat-Pregabalin · DIN 02494868 · $0.2324 PMS-Pregabalin · DIN 02359618 · $0.2324 Pregabalin · DIN 02403706 · $0.2324 Pregabalin · DIN 02405547 · $0.2324 Ran-Pregabalin · DIN 02392828 · $0.2324 Sandoz Pregabalin · DIN 02390825 · $0.2324 Teva-Pregabalin · DIN 02361175 · $0.2324
Shortage status: not checked (no credentials)
Other drugs in the same formulary class (28:12 Anticonvulsants) and how they are covered

Matched class: 28:12 Anticonvulsants

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: CLONAZEPAM, DIVALPROEX SODIUM, ETHOSUXIMIDE, LAMOTRIGINE, VALPROATE SODIUM Some products covered without a code (check the product listing): CARBAMAZEPINE, GABAPENTIN, PHENYTOIN (DIPHENYLHYDANTOIN), PHENYTOIN (DIPHENYLHYDANTOIN) SODIUM, PRIMIDONE, TOPIRAMATE, VALPROIC ACID 28:12 Anticonvulsants

GABAPENTIN

· 69 products · General benefit (49), Off-Formulary Interchangeable, not an ODB benefit (20) · strengths: 100mg, 300mg, 400mg, 600mg, 800mg · Cap, Tab

CARBAMAZEPINE

· 15 products · Listed, not a benefit (3), General benefit (6), Temporary benefit (2), Limited Use, codes 67 (4) · strengths: 100mg, 200mg, 400mg, 100mg/5mL · Chew Tab, ER Tab, LA Tab, Oral Susp, Tab

CLONAZEPAM

· 9 products · General benefit · strengths: 0.5mg, 2mg · Tab

DIVALPROEX SODIUM

· 9 products · General benefit · strengths: 125mg, 250mg, 500mg · Ent Tab

ETHOSUXIMIDE

· 4 products · General benefit · strengths: 250mg, 50mg/mL · Cap, O/L

LAMOTRIGINE

· 28 products · General benefit · strengths: 25mg, 100mg, 150mg · Tab

PHENYTOIN (DIPHENYLHYDANTOIN)

· 4 products · General benefit; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada (2), General benefit (2) · strengths: 6mg/mL, 25mg/mL, 50mg · O/L, Tab

PHENYTOIN (DIPHENYLHYDANTOIN) SODIUM

· 4 products · General benefit (3), Limited Use, codes 481, 657 (1) · strengths: 30mg, 100mg, 50mg/mL · Cap, Inj Sol (Preservative Free)

PRIMIDONE

· 4 products · General benefit (2), Listed, not a benefit (2) · strengths: 125mg, 250mg · Tab

TOPIRAMATE

· 54 products · Limited Use, codes 321 (2), Off-Formulary Interchangeable, not an ODB benefit (3), General benefit (49) · strengths: 15mg, 25mg, 50mg, 100mg, 200mg · Sprinkle Cap, Tab

VALPROATE SODIUM

· 5 products · General benefit · strengths: 50mg/mL · O/L

VALPROIC ACID

· 5 products · Listed, not a benefit (2), General benefit (3) · strengths: 250mg, 500mg · Cap, Ent Cap Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 28:12 and 11 more
Full class listing Related classes: 28:08 Analgesics, 28:10 Opiate Antagonists, 28:16 Psychotherapeutic Agents, 28:20 C.N.S. Stimulants, 28:24 Sedatives and Hypnotics, 28:36 Antiparkinsonian Agents, 28:92 Miscellaneous Central Nervous System Drugs Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: pain associated with fibromyalgia
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. No displayed matched alternative is a general benefit. DULOXETINE · Listed, not a benefit (2), General benefit (36) • Fibromyalgia pms-DULOXETINE is indicated for the management of pain associated with fibromyalgia (FM). PM: https://pdf.hres.ca/dpd_pm/00084896.PDF; date 2026-05-29; DIN 02429446; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-08-26
What the Health Canada label says it is for
1 INDICATIONS Adults LYRICA (pregabalin capsules) is indicated for the management of neuropathic pain associated with: • Diabetic peripheral neuropathy; • Postherpetic neuralgia; • Spinal cord injury LYRICA is indicated for the management of pain associated with fibromyalgia. The efficacy of LYRICA in the management of pain associated with fibromyalgia for up to 6 months was demonstrated in a placebo-controlled trial in patients who had initially responded to LYRICA during a 6-week open-label phase. 1.1 Pediatrics Pediatrics (< 18 years of age): No data are available to Health Canada; therefore, Health Canada has not authorized an indication for pediatric use (see 7.1.3 Pediatrics). 1.2 Geriatrics Geriatrics: Pregabalin oral clearance tended to decrease with increasing age. This decrease in pregabalin oral clearance is consistent with age-related decreases in creatinine clearance. Reduction of pregabalin dose may be required in patients who have age-related compromised renal function (see 7.1.4 Geriatrics). https://pdf.hres.ca/dpd_pm/00074814.PDF PM date: MAR 4, 2024 Source product: LYRICA; DIN 02268418; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.